Top

Published in:

Open Access 01-12-2018 | Letter

Comment on: ‘Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada’, Wilson et al., 22 June 2018

Authors: Ashleigh McGirr, Shehzad M. Iqbal, Jan Olbrecht, Lijoy Varghese

Published in: Infectious Diseases and Therapy | Issue 4/2018

Excerpt

In a recent article, Wilson et al. estimated the health and economic impact of switching the pediatric immunization program from the 13-valent (PCV-13) to the 10-valent (PHiD-CV) pneumococcal conjugate vaccine in Canada [1]. In this letter, we would like to highlight a number of methodologic issues that hamper the results that were not included in the original article. …

Wilson M, Wasserman M, Jadavi T, Postma M, Breton MC, Peloquin F, et al. Clinical and economic impact of a potential switch from 13-valent to 10-valent pneumococcal conjugate infant vaccination in Canada. Infect Dis Ther. 2018.

Government of Canada. Invasive Pneumococcal Disease: Surveillance of Invasive Pneumococcal Disease (IPD) 2018 [cited 2018 July 13]. https://www.canada.ca/en/public-health/services/immunization/vaccine-preventable-diseases/invasive-pneumococcal-disease/surveillance.html.

Streptococcus and STI Unit NML, Public Health Agency of Canada. National Laboratory Surveillance of Invasive Streptococcal Disease in Canada. 2016.

Busby C, Chesterley N. A Shot in the arm: how to improve vaccination policy in Canada C.D. Howe Institute. 2015.

Caro JJ, Briggs AH, Siebert U, Kuntz KM. Modeling good research practices–overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Med Decis Making. 2012;32(5):667–77.CrossRef

Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ, Paltiel AD, et al. Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6. Value Health. 2012;15(6):835–42.CrossRef

de Oliveira LH, Camacho LA, Coutinho ES, Martinez-Silveira MS, Carvalho AF, Ruiz-Matus C, et al. Impact and effectiveness of 10 and 13-valent pneumococcal conjugate vaccines on hospitalization and mortality in children aged less than 5 years in Latin American Countries: a systematic review. PLoS ONE. 2016;11(12):e0166736.CrossRef

SAGE. Executive Summary: SAGE 2017, Pneumococcal Conjugate Vaccine Session. 2017.

GSK Canada. Synflorix Product Monograph 2017 (cited 2018 Apr 30). https://ca.gsk.com/media/591956/synflorix.pdf.

10.

Deceuninck G, De Serres G, Boulianne N, Lefebvre B, De Wals P. Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada. Vaccine. 2015;33(23):2684–9.CrossRef

11.

Domingues CM, Verani JR, Montenegro Renoiner EI, de Cunto Brandileone MC, Flannery B, de Oliveira LH, et al. Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study. Lancet Respir Med. 2014;2(6):464–71.CrossRef

12.

Jokinen J, Rinta-Kokko H, Siira L, Palmu AA, Virtanen MJ, Nohynek H, et al. Impact of ten-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in Finnish children—a population-based study. PLoS ONE. 2015;10(3):e0120290.CrossRef

13.

Chuck AW, Jacobs P, Tyrrell G, Kellner JD. Pharmacoeconomic evaluation of 10- and 13-valent pneumococcal conjugate vaccines. Vaccine. 2010;28(33):5485–90.CrossRef

14.

Newall AT, Creighton P, Philp DJ, Wood JG, MacIntyre CR. The potential cost-effectiveness of infant pneumococcal vaccines in Australia. Vaccine. 2011;29(45):8077–85.CrossRef

15.

Comité sur l’immunisation du Québec (CIQ). Scientific advisory on the optimal schedule for childhood immunization against pneumococcal disease in Québec. Quebec: Institut national de santé publique Quebec. 2017.

Title: Comment on: ‘Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada’, Wilson et al., 22 June 2018
Authors: Ashleigh McGirr
Shehzad M. Iqbal
Jan Olbrecht
Lijoy Varghese
Publication date: 01-12-2018
Publisher: Springer Healthcare
Published in: Infectious Diseases and Therapy / Issue 4/2018
Print ISSN: 2193-8229
Electronic ISSN: 2193-6382
DOI: https://doi.org/10.1007/s40121-018-0220-3

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Comment on: ‘Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada’, Wilson et al., 22 June 2018

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 4/2018

A Markov Model to Estimate Mortality Due to HIV/AIDS Using Viral Load Levels-Based States and CD4 Cell Counts: A Principal Component Analysis Approach

HIV, HCV and HBV: A Review of Parallels and Differences

Prevalence of Clostridium Difficile-Associated Diarrhoea in Hospitalised Patients (Results of a Russian Prospective Multicentre Study)

Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial

Pan-Genotypic Hepatitis C Treatment with Glecaprevir and Pibrentasvir for 8 Weeks Resulted in Improved Cardiovascular and Metabolic Outcomes and Stable Renal Function: A Post-Hoc Analysis of Phase 3 Clinical Trials

Consider Syphilis in Case of Lymphopenia in HIV-Infected Men Who Have Sex with Men (MSM): A Single-center, Retrospective Study

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page